Medifoxamine

Medifoxamine is an antidepressant and anxiolytic drug that was formerly used in France for the treatment of depression and anxiety disorders, but has since been discontinued. Medifoxamine is a dopamine reuptake inhibitor, and is unique among most antidepressants in that it does not inhibit the reuptake of serotonin or norepinephrine. It also has anticholinergic properties.

Pharmacology

Medifoxamine acts as a dopamine reuptake inhibitor and sigma receptor agonist. It does not inhibit the reuptake of serotonin or norepinephrine. Medifoxamine also has anticholinergic properties, which can lead to side effects such as dry mouth, constipation, and cognitive impairment in some patients.

Medical uses

Medifoxamine was primarily used for the treatment of depression and anxiety disorders. It was particularly effective in patients with depression who also suffered from anxiety, due to its dual action as an antidepressant and anxiolytic.

Side effects

The most common side effects of medifoxamine include dry mouth, constipation, and cognitive impairment, which are likely due to its anticholinergic properties. Other side effects can include dizziness, nausea, and insomnia.

History

Medifoxamine was developed in the 1970s by the French pharmaceutical company Servier. It was marketed in France under the brand name Clédial. However, it has since been discontinued and is no longer available.

See also

• List of antidepressants
• List of anxiolytics

Medifoxamine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia